Antihypertensive effects of olmesartan compared with other angiotensin receptor
blockers: a meta-analysis.
Author(s): Wang L, Zhao JW, Liu B, Shi D, Zou Z, Shi XY.
Affiliation(s): Company 11, Second Military Medical University, Shanghai, People's Republic of
China.
Publication date & source: 2012, Am J Cardiovasc Drugs. , 12(5):335-44
OBJECTIVES: Angiotensin II type 1 receptor antagonists (angiotensin receptor
blockers [ARBs]) have been shown to be effective and well tolerated in
hypertensive patients. Olmesartan is the seventh angiotensin receptor blocker
licensed by the US Food and Drug Administration. The aim of this meta-analysis
was to determine the efficacy and tolerability of olmesartan medoxomil in
comparison with other ARBs.
DATA SOURCES: Reports of randomized controlled trials (RCTs) of olmesartan versus
other ARBs were identified through a systematic search of PubMed (up to July
2010), EMBASE (1980 to July 2010), SinoMed (up to July 2010), and the Cochrane
Central Register of Controlled Trials (Cochrane Library Issue 7, 2010).
REVIEW METHODS: Pertinent studies were selected through extensive searches of
PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and SinoMed. Two
of the authors abstracted data from the identified studies independently.
Criteria for inclusion in our meta-analyses were randomized clinical trials in
which patients were receiving an ARB and outcome data for blood pressure
reduction or the incidence of adverse events were available. Quantitative and
qualitative analyses of data from all RCTs meeting the criteria were performed.
Our meta-analysis was undertaken according to the Quality of Reporting
Meta-analyses (QUOROM) statement.
RESULTS: Twenty-two studies with data from 4892 patients were considered for
analyses. Olmesartan provided greater diastolic blood pressure (DBP) and systolic
blood pressure (SBP) reductions compared with losartan (DBP: 95% confidence
interval [CI] 0.59, 2.62; SBP: 95% CI 0.46, 5.92). Olmesartan provided greater
SBP reductions compared with valsartan (95% CI 0.29, 3.16). Similar blood
pressure response rates and incidence of adverse events were found with losartan,
valsartan, candesartan, and irbesartan.
CONCLUSION: Olmesartan provides better antihypertensive efficacy than losartan
and valsartan and has no association with an increased risk of adverse events in
comparison with losartan, valsartan, candesartan, and irbesartan.
|